Beam Therapeutics (BEAM) stock soared 10.78% on November 6th, 2024, after the company reported encouraging initial clinical data from its Phase 1/2 BEACON trial evaluating BEAM-101 for the treatment of sickle cell disease.
The data showed that BEAM-101, an investigational cell therapy administered via hematopoietic stem cell transplantation, achieved robust fetal hemoglobin (HbF) induction of over 60% and reduced sickle hemoglobin (HbS) to less than 40% in patients. This hemoglobin profile mimics that of individuals with sickle cell trait, who are typically asymptomatic.
Furthermore, BEAM-101 demonstrated a favorable safety profile consistent with myeloablative conditioning and stem cell transplant. Notably, the therapy facilitated rapid neutrophil engraftment, with all patients engrafting in under 20 days, potentially leading to shorter hospital stays.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。